United Therapeutics (UTHR)
(Delayed Data from NSDQ)
$331.04 USD
+8.81 (2.73%)
Updated Aug 8, 2024 04:00 PM ET
After-Market: $330.84 -0.20 (-0.06%) 7:58 PM ET
3-Hold of 5 3
B Value F Growth F Momentum D VGM
Brokerage Reports
United Therapeutics Corporation [UTHR]
Reports for Purchase
Showing records 401 - 420 ( 601 total )
Company: United Therapeutics Corporation
Industry: Medical - Drugs
$350 Million for Rare Pediatric Disease Voucher Makes Unituxin Highly Profitable, in Our View; Reiterate OUTPERFORM but Increase Price Target to $244
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Unituxin(TM) Granted Market Authorization by the European Commission; Reiterate OUTPERFORM and $209 Price Target.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
The Week Ahead in Life Sciences - Upcoming Events for the Week of August 17
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
August and 2015 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Increased IP Clarity, Uptick in Orenitram Revs, and Likely Revised Buyback Program to Keep Investors Engaged; Reit Buy
Provider: H.C. WAINWRIGHT & CO., INC.
Analyst: FEIN A
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Q2 Was Choppy; However, We See Intact Annual Growth with Orenitram and Adcirca as Drivers; Reiterate OUTPERFORM and Raising PT to $209
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
The Week Ahead in Life Sciences - Upcoming Events for the Week of July 27
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Q2:15 Preview: In Our View, Consensus Revenues Are Achievable; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
July and 2015 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Emerging Pharmaceuticals - June and 2015 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
May and 2015 Emerging Pharmaceuticals Catalysts
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Buyback Maintains Share Momentum During Orenitram Launch, IP Litigation, and Remodulin Pump Hiccup; Reit Buy and $175 PT
Provider: H.C. WAINWRIGHT & CO., INC.
Analyst: FEIN A
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Q1 Financials: We Believe Weak Q1 Sales Transient and Growth Intact--Load Up on Weakness
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L